The online version of this article (https://doi.org/10.1007/s00432-020-03141-w) contains supplementary material, which is available to authorized users.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Clinical practice guidelines provide recommendations for the management of diseases. In orphan conditions such as uveal melanoma (UM), guideline developers are challenged to provide practical and useful guidance even in the absence of high-quality evidence. Here, we assessed the methodological quality and identified deficiencies of international guidelines on UM as a base for future guideline development.
A systematic search was carried out in guideline databases, Medline and Embase until 27th May 2019 for guidelines on UM published between 2004 and 2019. Five independent reviewers assessed the methodological quality of the identified guidelines using the instruments “Appraisal of Guidelines for Research and Evaluation II” (AGREE II) and AGREE-REX (Recommendation EXcellence). Descriptive analysis was performed and subgroup differences were explored with the Kruskal–Wallis (H) test. The relationship between the individual domains and items of the instruments were examined using Spearman’s correlation.
Five guidelines published from 2014 to 2018 by consortia of the United States of America, Canada and the United Kingdom (UK) were included. The highest scores were obtained by the UK guideline fulfilling 48–86% of criteria in AGREE II and 30–60% for AGREE-REX. All guidelines showed deficiencies in the domains “editorial independence”, “applicability”, and “recommendation”. Subgroup differences were identified only for the domain “editorial independence”.
The UK guideline achieved the highest scores with both instruments and may serve as a basis for future guideline development in UM. The domains “editorial independence”, “recommendation”, and “applicability” were identified as methodological weaknesses and require particular attention and improvement in future guidelines.
AGREE-REX Research Team (2019). The Appraisal of Guidelines Research & Evaluation—Recommendation EXcellence (AGREE-REX) [Electronic version]. https://www.agreetrust.org/wp-content/uploads/2019/04/AGREE-REX-2019.pdf. Accessed 18 Nov 2019
Bedikian AY (2006) Metastatic uveal melanoma therapy: current options. Int Ophthalmol Clin 46:151–166 CrossRef
Brouwers MC, Florez ID, McNair SA, Vella ET, Yao X (2019) Clinical practice guidelines: tools to support high quality patient care. Semin Nucl Med 49:145–152. https://doi.org/10.1053/j.semnuclmed.2018.11.001 CrossRefPubMed
Dans AL, Dans LF (2010) Appraising a tool for guideline appraisal (the AGREE II instrument). J Clin Epidemiol 63:1281–1282. https://doi.org/10.1016/j.jclinepi.2010.06.005 CrossRefPubMed
Heppt MV et al (2017a) Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition. Eur J Cancer 82:56–65. https://doi.org/10.1016/j.ejca.2017.05.038 CrossRefPubMed
Heppt MV et al (2017b) Immune checkpoint blockade for unresectable or metastatic uveal melanoma: a systematic review. Cancer Treat Rev 60:44–52. https://doi.org/10.1016/j.ctrv.2017.08.009 CrossRefPubMed
Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174 CrossRef
Mallone S et al (2012) Descriptive epidemiology of malignant mucosal and uveal melanomas and adnexal skin carcinomas in Europe. Eur J Cancer 48:1167–1175. https://doi.org/10.1016/j.ejca.2011.10.004 CrossRefPubMed
Mathis T et al (2018) Management of uveal melanomas, guidelines for oncologists. Bull Cancer 105:967–980. https://doi.org/10.1016/j.bulcan.2018.07.011 CrossRefPubMed
Nag S, Quivey JM, Earle JD, Followill D, Fontanesi J, Finger PT, American Brachytherapy S (2003) The American Brachytherapy Society recommendations for brachytherapy of uveal melanomas. Int J Radiat Oncol Biol Phys 56:544–555 CrossRef
Nathan P et al (2015) Uveal melanoma UK national guidelines. Eur J Cancer 51:2404–2412. https://doi.org/10.1016/j.ejca.2015.07.013 CrossRefPubMed
National Cancer Institute (2019) Intraocular (Uveal) Melanoma treatment (PDQ®)–health professional version. https://www.cancer.gov/types/eye/hp/intraocular-melanoma-treatment-pdq#_84. Accessed 19 Nov 2019
National Comprehensive Cancer Network (NCCN) (2018) Clinical Practice Guidelines in Oncology Uveal Melanoma, Version I. 2018
National Institute for Health and Care Excellence (2019) IMCgp100 for treating metastatic uveal melanoma (ID1441). https://www.nice.org.uk/guidance/indevelopment/gid-ta10428. Accessed 20 Nov 2019
Leitlinienprogramm Onkologie (2019) (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Diagnostik, Therapie und Nachsorge des Melanoms, Langversion 3.2, 2019, AWMF Registernummer: 032/024OL, https://www.leitlinienprogramm-onkologie.de/leit-linien/melanom/. Accessed 18 Nov 2019
Rico Iturrioz R, Gutierrez-Ibarluzea I, Asua Batarrita J, Navarro Puerto MA, Reyes Dominguez A, Marin Leon I, de la Blanca Briones EP (2004) Assessment of clinical practice guidelines evaluation. Scales and criteria. Rev Esp Salud Publica 78:457–467. https://doi.org/10.1590/s1135-57272004000400004 CrossRefPubMed
Scottish Intercollegiate Guidelines Network (SIGN) (2017). Cutaneous melanoma (SIGN publication no. 146). https://www.sign.ac.uk/assets/sign146.pdf. Accessed 20 Dec 2019
Shoushtari AN, Carvajal RD (2014) GNAQ and GNA11 mutations in uveal melanoma. Melanoma Res 24:525–534. https://doi.org/10.1097/CMR.0000000000000121 CrossRefPubMed
Simpson ER et al (2014) The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. Brachytherapy 13:1–14. https://doi.org/10.1016/j.brachy.2013.11.008 CrossRef
Skalicky SE, Holt PE, Giblin M, Taylor S, Conway RM (2008) Australian cancer network clinical practice guidelines for the management of ocular and periocular melanoma: an evidence-based literature analysis. Clin Experiment Ophthalmol 36:646–658. https://doi.org/10.1111/j.1442-9071.2008.01815.x CrossRefPubMed
Steeb T, Wessely A, Ruzicka T, Heppt MV, Berking C (2018) How to MEK the best of uveal melanoma: a systematic review on the efficacy and safety of MEK inhibitors in metastatic or unresectable uveal melanoma. Eur J Cancer 103:41–51. https://doi.org/10.1016/j.ejca.2018.08.005 CrossRefPubMed
Swetter SM et al (2019) Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol 80:208–250. https://doi.org/10.1016/j.jaad.2018.08.055 CrossRefPubMed
- Guidelines for uveal melanoma: a critical appraisal of systematically identified guidelines using the AGREE II and AGREE-REX instrument
Kinan M. Hayani
Markus V. Heppt
- Springer Berlin Heidelberg
Journal of Cancer Research and Clinical Oncology
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
Neu im Fachgebiet Onkologie
Mail Icon II